Journal article
Alemtuzumab in Chronic Lymphocytic Leukemia
Abstract
QUESTIONS: With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (cll)?What toxicities are associated with the use of alemtuzumab?Which patients are more likely-or less likely-to benefit from treatment with alemtuzumab?
PERSPECTIVES: Evidence was selected and reviewed by one member …
Authors
Fraser G; Smith CA; Imrie K; Meyer R; Care THDSGCCOPIE-B
Journal
Current Oncology, Vol. 14, No. 3, pp. 96–109
Publisher
MDPI
Publication Date
June 2007
DOI
10.3747/co.2007.118
ISSN
1198-0052